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A New Concept of Co-mutagenicity
from a Phenomenon Forgotten for
the Past Two Decades: Is It More
Important than Previously Expected?
In 1977, during the course ofstudies on the mutagenic principle in
tryptophan pyrolysates, it was incidentally observed that the muta-
genic activity towards Salmonella typhimurium TA98 in the pres-
ence of S9 mix was dramatically reduced or almost lost at certain
fractionation steps. Interestingly, combining some nonmutagenic
fractions with those that showed only very weak or no mutagenici-
ty resulted in restoration ofthe original level ofmutagenic activity.
One of the fractions contained norharman and harman, both of
which are nonmutagenic ,B-carboline derivatives to S. typhimurium
TA98 in the presence of S9 mix, while the others contained
unknown mutagenic compounds or heterocyclic amines at low lev-
els (1). This phenomenon, in which nonmutagenic ,B-carbolines
augmented the mutagenicity ofnonmutagenic compounds or dras-
tically enhanced the weak mutagenicity, was termed co-mutagenic-
ity. The co-mutagenicity was onlydemonstrated when P-carbolines
were incubated with other compounds in the presence ofS9 mix.
The most clear-cut demonstration ofco-mutagenicity was made
by incubation ofnorharman with aniline in the presence ofS9 mix.
Aniline alone showed no mutagenic activity to S. typhimurium
TA98. Typical data are shown in Table 1 (2). The case oftoluidines
(aminotoluenes) is also remarkable. Among three toluidine isomers,
o- and m- isomers showed mutagenicity in the presence ofnorhar-
man, whereas p-toluidine remained inactive (see Table 2) (2,3).
Moreover, yellow OB and N-nitrosodiphenylamine, which are
themselves nonmutagenic, were shown to be mutagenic to S.
typhimurium TA98 with S9 mix only in the presence ofnorharman
(4,5). Although less dramatic, the mutagenicity of 4-dimethyl-
aminoazobenzene was also enhanced bynorharman (4).
The mechanism and significance ofco-mutagenicity has awaited
clarification since the time ofits first discovery over two decades ago.
RecentlyTotsuka et al. (6) found that norharman can conjugatewith
aniline to form a third compound (I) in the presence ofS9 mix (6).
Table 1. Mutagenicity of norharman (200 pg/plate) and aniline (100 pg/plate)
in SalmonellatyphimuriumTA98 in the presence ofS9 mix
Revertants/plate
Norharman and aniline 3,400
Norharman 0
Aniline 0
Table2. Mutagenicity of norharman (200 pg/plate) with toluidine isomers (100
pg/plate) in Salmonella typhimuriumTA98 in the presence of S9 mix
Revertants/plate
Norharman + o-toluidine 6,990
Norharman + m-toluidine 62
Norharman + p-toluidine 0
No mutagenic activity was observed with any ofthe compounds alone.
The compound (I) was purified and
the structure was determined, as
shown in Figure 1. It is very impor-
tant that the chemically synthesized
compound (I), 9-(4'-aminophenyl)-
9 H- p yr i do [3 , 4- b] i n do 1e
(aminophenylnorharman), still
required the metabolic activation by
S9 mix to exert mutagenicity to S.
typhimurium TA98. This compound is easily organically synthesized
in high yield with norharman andp-bromonitrobenzene as starting
materials. Furthermore, DNA extracted from S. typhimurium TA98
incubated with norharman plus aniline or from S. typhimurium
TA98 incubated with aminophenylnorharman, both in the presence
of S9 mix, demonstrated the same DNA adduct pattern when
assessed using the32P-postlabeling method (6).
Norharman and harman are present at relatively high concen-
trations in natural and industrial environments; for example, ciga-
rette tar contains norharman and harman at levels of 3.3-14.1
fg/cigarette. They can also be formed in vivo from tryptamine, a
decarboxylated form of the amino acid tryptophan. Tryptamine
nonenzymatically reacts with formaldehyde or the Cl-unit
metabolite and acetaldehyde, abundant after ethanol ingestion and
in diabetic patients, to yield norharman and harman, respectively.
Ushiyama et al. (7) found that the urine of inpatients receiving
only parenteral alimentation contained norharman and harman,
suggesting in vivo formation of 3-carbolines. Therefore, it is likely
that co-mutagenic events may occur in the human body.
The structure ofaminophenylnorharman formed from norhar-
man and aniline has an N-C bond between the indole nitrogen
and C-4 position ofaniline. Hydroxylation at the C-4 position of
aniline is possibly catalyzed by a member ofthe cytochrome P450
family. However, norharman andp-aminophenol did not yield any
mutagenicity to S. typhimurium TA98 when incubated in the pres-
ence ofS9 mix; thus,p-aminophenol is presumably not an ultimate
metabolite for the formation ofaminophenylnorharman.
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Figure 1. The formation of compound from the co-mutagen norhorman with
aniline in the presence of S9 mix and the structure of compound 1.
Volume 106, Number 1 1, November 1998 * Environmental Health Perspectives A 5Z22Editorial
Aminophenylnorharman is genotoxic and causes cellular dam-
age in rats; it is also likely to be carcinogenic in vivo. Hepatic degen-
eration, erosive changes in the urinary bladder with hematuria, and
testicular toxicitywere observed in rats administered 20 mg/kg body
weight ofthe compound by gavage six times during 1 week. In this
context, the International Agency for Research on Cancer report
suggesting carcinogenicity of aniline in rats and o-toluidine in
rodents is also ofinterest (8).
The science of co-mutagenesis opens new vistas for organic
chemistry, metabolism offoreign substances, DNA adduct forma-
tion, DNA repair, co-carcinogenicity, in vitro effects on cultured
mammalian cells, in vivo toxicity, pharmacological action, and in
vivo carcinogenicity. The significance ofco-mutagenesis may hith-
erto have been very much underestimated and clearly warrants
detailed attention.
Takashi Sugimura
National Cancer Center
Tokyo, Japan
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